TXR-1208

TXR-1208 is a **preclinical small molecule** drug candidate discovered by **twoXAR Pharmaceuticals** and associated with **Aria Pharmaceuticals** for the potential treatment of **chronic kidney disease**. Publicly available information indicates that it was identified using the company's AI-driven drug discovery platform and has shown **significant efficacy and good tolerability in preclinical studies**, including reductions in **kidney fibrosis**, **inflammation**, **myofibroblast activation**, and **infiltrating T cells** in a unilateral ureteral obstruction mouse model. Its **precise molecular target and detailed mechanism of action have not been publicly disclosed**, but it has been described as having a **novel mechanism of action** in kidney disease.